Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mukul Sharma

Showing results (211-220 of 225) with videos related to

Pageof 23
Sort By:
The Lancet. Neurology|December 15, 2023
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
The New England Journal of Medicine|May 17, 2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined SourceRobert G Hart, Mukul Sharma, Hardi Mundl, et al.
European Stroke Journal|January 30, 2026
Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke preventionMukul Sharma, Qiang Dong, Teruyuki Hirano, et al.
The New England Journal of Medicine|April 15, 2026
Asundexian for Secondary Stroke PreventionMukul Sharma, Qiang Dong, Teruyuki Hirano, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 13, 2019
Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegenerationEric E Smith, Geert Jan Biessels, François De Guio, et al.
The Canadian Journal of Cardiology|May 21, 2010
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyDaniel G Hackam, Nadia A Khan, Brenda R Hemmelgarn, et al.
The Canadian Journal of Cardiology|July 30, 2017
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) TrialJackie Bosch, John W Eikelboom, Stuart J Connolly, et al.
Annals of Internal Medicine|June 2, 2025
Effects of a Hypotension-Avoidance Versus a Hypertension-Avoidance Strategy on Neurocognitive Outcomes After Noncardiac SurgeryMaura Marcucci, Matthew T V Chan, Thomas W Painter, et al.
The Canadian Journal of Cardiology|April 2, 2013
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionDaniel G Hackam, Robert R Quinn, Pietro Ravani, et al.
The Canadian Journal of Cardiology|August 2, 2011
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyDoreen M Rabi, Stella S Daskalopoulou, Raj S Padwal, et al.
Pageof 23

Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
The Lancet. Neurology|December 15, 2023
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
The New England Journal of Medicine|May 17, 2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined SourceRobert G Hart, Mukul Sharma, Hardi Mundl, et al.
European Stroke Journal|January 30, 2026
Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke preventionMukul Sharma, Qiang Dong, Teruyuki Hirano, et al.
The New England Journal of Medicine|April 15, 2026
Asundexian for Secondary Stroke PreventionMukul Sharma, Qiang Dong, Teruyuki Hirano, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 13, 2019
Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegenerationEric E Smith, Geert Jan Biessels, François De Guio, et al.
The Canadian Journal of Cardiology|May 21, 2010
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyDaniel G Hackam, Nadia A Khan, Brenda R Hemmelgarn, et al.
The Canadian Journal of Cardiology|July 30, 2017
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) TrialJackie Bosch, John W Eikelboom, Stuart J Connolly, et al.
Annals of Internal Medicine|June 2, 2025
Effects of a Hypotension-Avoidance Versus a Hypertension-Avoidance Strategy on Neurocognitive Outcomes After Noncardiac SurgeryMaura Marcucci, Matthew T V Chan, Thomas W Painter, et al.
The Canadian Journal of Cardiology|April 2, 2013
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionDaniel G Hackam, Robert R Quinn, Pietro Ravani, et al.
The Canadian Journal of Cardiology|August 2, 2011
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyDoreen M Rabi, Stella S Daskalopoulou, Raj S Padwal, et al.
Pageof 23